Evidence map›Paper›PMID 31615558›Full record

ArticleDiagnostic pathology2019

JAZF1-SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report.

Koto Fujiishi, Shigenori Nagata, Rieko Kano, Chiaki Kubo, Maasa Shirayanagi, Megumi Ozaki, Takashi Yamamoto, Katsuyuki Nakanishi, Shoji Kamiura, Shin-Ichi Nakatsuka

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Polycomb Repressive Complex 2 in Oncology.Cancer treatment and research · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Update on Endometrial Stromal Tumours of the Uterus.Diagnostics (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Koto FujiishiDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Shigenori NagataDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan. nagata-si@mc.pref.osaka.jp.ORCID http://orcid.org/0000-0002-5455-6886
Rieko KanoDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Chiaki KuboDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Maasa ShirayanagiDepartment of Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Megumi OzakiDepartment of Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Takashi YamamotoDepartment of Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Katsuyuki NakanishiDepartment of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Osaka, Japan.
Shoji KamiuraDepartment of Gynecologic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Shin-Ichi NakatsukaDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Osaka International Cancer Institute · JPOsaka International Cancer Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow-grade endometrial stromal sarcoma (ESS) is rare mesenchymal neoplasm, recently specified as harboring JAZF1-SUZ12 rearrangement. Typical JAZF1-SUZ12 ESS is slow growing, in which high uptake of fluorodeoxyglucose (FDG) on positron emission tomography (PET) and subserosal masses are quite unusual. CASE PRESENTATION: A 69-year-old Japanese woman complained of urinary incontinence. Pelvic magnetic resonance imaging showed uterine lesions composed of (1) a 9 × 8 × 7-cm mass protruding from the right-anterior wall, (2) a 4.5-cm mass attached to the right-posterior wall, and (3) a 6.5-cm intramural mass in the fundus. FDG-PET demonstrated maximum standardized uptake value of 13.28 confined to the two subserosal masses (1 & 2) in contrast to no uptake of the intramural mass (3). She was diagnosed with a high-grade uterine sarcoma concomitant with leiomyomas and underwent total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The removed uterus had three tumors-two in the right-anterior and right-posterior subserosa, respectively, and the remaining in the fundal myometrium. Microscopically, the three tumors shared morphologic features characterized by neoplastic cells similar to proliferative-phase endometrial stromal cells, in which neither round-cell component, pleomorphism, nor high mitotic activity was recognized. Nuclear cyclin D1 immunostaining was identified 50% of neoplastic cells in the two subserosal tumors (1 &2) whereas < 1% positive cells in the intramural component (3). Reverse transcriptase-polymerase chain reaction showed the same-sized electrophoretic bands indicating JAZF1-SUZ12 gene fusion shared by the three uterine tumors and a focal tumor extension into the extrauterine vein. The patient is alive without evidence of recurrence at 14 months after surgery.

conclusionsPathologists and clinicians should not exclude the possibility of JAZF1-SUZ12 ESS even when uterine subserosal masses demonstrate extraordinary FDG uptake on PET. Molecular analysis is helpful for diagnostic confirmation of JAZF1-SUZ12 ESS with a complex growth pattern.

Indexed as

AgedCo-Repressor ProteinsDNA-Binding ProteinsEndometrial NeoplasmsFemaleHumansIn Situ Hybridization, FluorescenceNeoplasm ProteinsNeoplasm Recurrence, LocalPolycomb Repressive Complex 2Sarcoma, Endometrial StromalTranscription FactorsCo-Repressor ProteinsDNA-Binding ProteinsJAZF1 protein, humanNeoplasm ProteinsPolycomb Repressive Complex 2SUZ12 protein, humanTranscription FactorsCyclin D1Endometrial stromal sarcomaJAZF1–SUZ12Positron emission tomographySubserosal mass

Identifiers

PMID31615558
PMCPMC6792225
OpenAlexW2980758406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.